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Surra is an animal pathogenic protozoan infection, caused by Trypanosoma evansi, that develops into a fatal
wasting disease. Control measures rely on diagnosis and treatment. However, with the continuous emergence
of drug resistance, this tactic is failing, and the pressing need for new chemotherapeutic agents is becoming
critical. With the introduction of novel aromatic diamidines, a new category of antitrypanosomal drugs was
discovered. Nevertheless, their efficacy within a T. evansi-infected mouse model was not known. In total, 30
compounds previously selected based on their in vitro activity were tested in a T. evansi mouse model of
infection. Six of the compounds were capable of curing T. evansi-infected mice at drug doses as low as 0.5 and
0.25 mg/kg of body weight administered for 4 consecutive days, and they were more effective than the standard
drugs suramin, diminazene, and quinapyramine. After all selection criteria were applied, three diamidine
compounds (DB 75, DB 867, and DB 1192) qualified as lead compounds and were considered to have the
potential to act as preclinical candidates against T. evansi infection.
Surra is an animal pathogenic protozoan infection, caused
by Trypanosoma evansi, that develops into a fatal wasting dis-
ease. It is mechanically transmitted by biting flies of the genera
Tabanus, Stomoxys, and Lyperosia. No intermediate hosts and
no insect developmental cycles have been identified yet (8).
Control measures for protozoan diseases such as Surra rely on
treatment and vector control and, to a much lesser extent, on
chemoprophylaxis. In the case of Surra, drugs containing an-
titrypanosomal properties usually are administered once an
infection already has been established (7, 17). However, with
the continuous emergence of drug resistance, this tactic is
failing, and the pressing need for new, alternative chemother-
apeutic agents is becoming critical (16, 20). Moreover, the
prospect of a vaccination against T. evansi infection appears
nonexistent, largely based upon the phenomenon of the anti-
genic variation of trypanosomes in general.
With the introduction of novel aromatic diamidines, a new
category of antitrypanosomal drugs was discovered (9, 18, 21).
The dicationic spacer between the active moieties remains the
same, yet the active groups are altered to include structure-
activity relationship information obtained from previous com-
pounds. Several of these dicationic compounds have shown
great efficacy in vitro against both human and animal patho-
genic trypanosome species. A previous study of these diami-
dine compounds enabled the positive selection of diamidine
compounds exhibiting high in vitro activity against both a Chi-
nese T. evansi reference strain and a P2 transporter knockout
strain, which have low cytotoxicity and low in vivo toxicity (15
and K. Gillingwater, A. Kumar, M. A. Ismail, R. K. Arafa,
C. E. Stephens, D. W. Boykin, and R. Brun, submitted for
publication). The 50% inhibitory concentrations (IC50s) of the
lead compounds tested ranged from 10.5 to 1.7 ng/ml. The
IC50s of the four existing agents are 87.6, 12.5, 1.1, and 0.1
ng/ml for suramin, diminazene, cymelarsan, and quinapyra-
mine, respectively (Gillingwater et al., submitted). Since dia-
midines are actively taken up by transporters, any alterations to
these transporters will affect the compounds’ modes of action,
selectivity, and development of drug resistance. By having
tested the compounds against a P2 knockout strain, com-
pounds reliant on P2 transportation alone can be identified.
The aim of this study was to investigate 30 previously se-
lected diamidine compounds in vivo in a T. evansi mouse
model of infection.
MATERIALS AND METHODS
Trypanosome strain. The Trypanosoma evansi STIB 806K strain was used for
all in vivo experiments performed in this study. It was isolated from a water
buffalo in China in 1983 (15). This strain was cloned and adapted to axenic
culture (2).
Mice. Female NMRI mice, weighing 22 to 25 g, were used for the in vivo
experiments. All mice were specific pathogen free (SPF) and were maintained in
standard Macrolon type II cages at 22°C and with a relative humidity of 60 to
70%. Water and pelleted food was provided ad libitum. All in vivo experiments
performed complied with the regulations set out by the Swiss Federal Veterinary
Office.
Standard trypanocidal drugs. Suramin (Germanin; Bayer, Leverkusen, Ger-
many), diminazene aceturate (D-7770; Sigma, St. Louis, MO), cymelarsan
(MelCy; Rhône Mérieux, Toulouse, France), and quinapyramine sulfate (Tryp-
acide; May & Baker, Lagos, Nigeria) were used as the standard drugs in this
study.
Diamidine compounds. The diamidine compounds were synthesized previ-
ously in the laboratories of David Boykin and Richard Tidwell. For the in vivo
experiments, the diamidine compounds were selected by means of their previ-
ously demonstrated in vitro activity against T. evansi strains (several reference
strains and a P2 knockout strain) and the absence of toxicity shown in prelimi-
nary toxicity trials performed in vivo for doses of up to 100 mg/kg of body weight
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(Gillingwater et al., submitted). Of the 67 compounds tested, 69% showed no
acute toxicity at doses of 100 mg/kg.
Culture medium. Bloodstream-form trypanosomes were cultivated in mini-
mum essential medium (MEM) (a powder; no. 11400-033; GIBCO-BRL) with
Earle’s salts supplemented with 25 mM HEPES, 1 g/liter additional glucose, 2.2
g/liter NaHCO3, and 10 ml/liter MEM nonessential amino acids (50 concen-
tration). The medium then was further supplemented according to Baltz et al. (2)
by adding 1% of a 1.2 mM stock of 2-mercaptoethanol, 1% of a stock consisting
of 100 mM sodium pyruvate and 50 mM hypoxanthine, and 15% heat-inactivated
horse serum. The complete medium is called Baltz MEM (BMEM).
Stock solutions and dilutions. A 1.5-mg amount of each compound was
weighed out in powder form and dissolved in 15 ml of sterile distilled water to
provide a 0.1 mg/ml stock solution. From these stock solutions, further com-
pound dilutions were made depending on the dose being tested. Stock solutions
and compound dilutions were made fresh on the day of administration and for
each experiment.
In vivo experiments. Female NMRI mice were divided into groups of four
mice each. Mice were infected with 104 parasites in 0.25 ml BMEM with in vitro
cultures of the STIB 806K T. evansi reference strain using an intraperitoneal
(i.p.) route of infection. A parasitemia of 106 parasites per ml blood was allowed
to develop for 72 h before treatment. All treatment was given i.p. on days 3 to 6
postinfection. Thereafter, the parasitemia was checked twice a week for the first
2 weeks and once per week thereafter using a tail blood examination technique
until day 60 postinfection. This 2-month experimental follow-up period after
treatment was used to account for any possible relapses. Subsequently, any
surviving and aparasitemic mice were considered cured. Untreated mice survive,
on average, 7 days postinfection.
RESULTS
The four standard drugs currently in use against Trypano-
soma evansi infection and 30 selected diamidine compounds
were tested in vivo in this study. The results of the in vivo inves-
tigations for the four standard drugs can be seen in Table 1.
The standard diamidine drug, diminazene aceturate, was
capable of curing only 3/4 mice at a 1 mg/kg dose administered
for 4 consecutive days. Twice this amount (2 mg/kg) actually
was required to achieve the lowest curative dose. Cymelarsan
demonstrated the highest efficacy, with a lowest curative dose
of 0.0625 mg/kg administered for 4 consecutive days. At a dose
of 1 mg/kg administered for 4 consecutive days, both quina-
pyramine and suramin were able to cure 4/4 mice. However, as
the dose was reduced to 0.5 and 0.25 mg/kg, only 3/4 and 1/4
mice were cured, respectively, for quinapyramine, and only 3/4
and 0/4 mice were cured, respectively, for suramin.
Thirty selected diamidine compounds were investigated for
in vivo efficacy in a mouse model. The various doses tested,
showing the number of mice cured above the number originally
infected, with the average survival results (in days), can be seen
in Table 2. Four compounds, DB 867, DB 930, DB 1192, and
DB 1283, produced minimum curative doses of 0.5 mg/kg ad-
ministered for 4 consecutive days. The compounds DB 820 and
DB 75 produced the lowest curative doses of 0.25 and 0.20
mg/kg, respectively. At these relatively low doses, 4/4 mice
were cured, and all six compounds were more effective at
curing T. evansi-infected mice than the standard drugs
suramin, diminazene, and quinapyramine. The lowest curative
dose of cymelarsan (0.0625 mg/kg administered for 4 consec-
utive days) remains four to eight times lower than the lowest
curative doses of these six diamidine compounds.
In summary, only these six diamidine compounds (DB 75,
DB 820, DB 867, DB 930, DB 1192, and DB 1283) showed a
better efficacy in the mouse model than three of the four
TABLE 1. In vivo investigations of four standard drugs given on 4 consecutive days to NMRI mice infected with T. evansi (STIB 806K)a













Quinapyramine Quinoline pyrimidine 1 4/4 60*
0.5 3/4 57
0.25 1/4 41
Suramin Sulfonated naphthalene 1 4/4 60*
0.5 3/4 51
0.25 0/4 11
a The asterisk indicates that all mice were cured at this dose. Numbers in boldface indicate the lowest curative dose of that drug.
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TABLE 2. In vivo investigations of selected diamidine compounds given on 4 consecutive days to NMRI mice infected with














DB 690 (9) Diphenyl furan 1 4/4 60*
0.5 3/4 57
0.25 1/4 41
DB 820 (14) Aza-furan 0.5 4/4 60*
0.25 4/4 60*
0.125 2/4 50
DB 828 (3) Diaryl furan 1 0/4 23








DB 1012 (12) Diaryl furan 1 0/4 13
DB 1017 () Diphenyl furan 0.5 1/4 43
DB 1173 (4) Diaryl furan 0.5 0/4 15
Azoles
DB 850 () Benzimidazole 0.5 0/4 16
DB 853 (11) Benzimidazole 1 0/4 18
DB 989 () Benzimidazole 0.5 0/4 27
Continued on following page










DB 1052 () Thiazole 1 3/4 53
DB 1055 (11) Benzimidazole 0.5 0/4 12
16 DAP 095 Isoxazole 1 4/4 60*
0.5 1/4 29
Other
DB 211 (14) Pyrimidine 0.5 0/4 15
DB 320 (6) Diphenyl pyrrole 1 3/4 49
DB 877 (12) Biphenyl 1 1/4 35
0.2 0/4 12
DB 1019 (10) Aza biphenyl 1 1/4 28
DB 1044 () Diaryl pyridine 0.5 0/4 16
DB 1171 (19) Indole 0.5 1/4 30
DB 1172 () Indole 1 1/4 39
DB 1191 () Indole 0.5 0/4 7




DB 1220 (1) Terphenyl 0.5 0/4 13
DB 1258 (10) Terphenyl 0.5 0/4 7
Continued on following page
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standard drugs, and these qualify for further investigation in a
larger animal model.
DISCUSSION
The aim of this study was to investigate 30 selected diami-
dine compounds that have been found to be highly active in
vitro against the reference STIB 806K Trypanosoma evansi
strain. These diamidine compounds were chosen not only for
their antitrypanosomal activity against T. evansi strains but also
for their reduced potential to develop drug resistance, as de-
termined by previous activity against a genetic P2 transporter
knockout strain (TbAT1 K.O.) (Gillingwater et al., submitted).
Many diamidines are known to be taken up into the parasite
via the P2 transporter, so testing against a strain known not to
possess a P2 transporter enables the elimination of such com-
pounds. Compounds that still are actively taken up efficiently
by the P2 knockout strain demonstrate alternative uptake
pathways and hence may still be effective against drug-resistant
populations. The low cytotoxicity against mammalian cells and
the absence of toxicity within a mouse model also are impor-
tant criteria for the specific selection of these diamidine com-
pounds (Gillingwater et al., submitted). By determining the in
vivo chemotherapeutic efficacy of these 30 compounds, it was
possible to further select the most efficient, nontoxic com-
pounds, which eventually could be developed into alternatives
to the four standard drugs currently in use.
The standard drugs were able to cure 4/4 mice at drug doses
of 1 mg/kg (for suramin and quinapyramine), 2 mg/kg (for
diminazene), and 0.0625 mg/kg (for cymelarsan) administered
for 4 consecutive days. In this mouse model, the diamidine
diminazene appears to have the least efficacy among all of the
standard drugs currently on the market. In contrast, cymelar-
san demonstrates the best efficacy, yet the costs of this drug,
which are higher than those of other trypanocidal drugs (ap-
proximately $10 for a camel), coupled with its limited avail-
ability throughout the world (it is available only in the Middle
East and Africa), overshadow its beneficial properties.
From the 30 compounds tested, 8 (27%) cured at 1 mg/kg
administered for 4 consecutive days and 6 (20%) cured at 0.5
mg/kg administered for 4 consecutive days. Since the general aim
of this study was to discover potential lead compounds possessing
greater activity than the standard drugs, only the best six com-
pounds (providing cure at 0.5 mg/kg) were selected.
Another selection criterion for clinical candidate compounds
capable of entering into clinical trials included the cost assess-
ment and large-scale production of a compound. Given that an
alternative compound against T. evansi infection would signif-
icantly benefit many communities within developing countries,
an ideal candidate should be cheap. Therefore, an element of
cost-effectiveness was applied to establish which compounds
contained the most advantageous properties for large-scale
production. Compounds requiring expensive starting materi-
als, as well as compounds involving complex and numerous
synthetic steps, would increase the cost of goods. It was rec-
ognized that some of the compounds included a lengthy and
complicated synthesis, which would pose problems of practi-
cality and cost. DB 930 and DB 1283 have a complicated
synthesis, which would increase the overall costs of these com-
pounds, and as a result, they were not selected for continued
investigation.
The aza-furan compound DB 820 currently is under inves-
tigation as a potential clinical candidate for human African
trypanosomiasis. The selection and safety criteria for drugs
intended for human use differ from those for drugs intended
for veterinary use. Even though a common drug for both hu-
man and veterinary use would appear economically beneficial,
it would be rendered useless in both cases should the parasites
involved become resistant to it. Hence, compounds already
under investigation for human use were avoided in this study.
Consequently, DB 820 was removed from the list of candidates














DB 1342 () Pyrrole 0.5 1/4 34
3 KEG 083 Pentamidine analogue 1 0/4 29
5 MAA 101 Pentamidine analogue 1 1/4 29
a The asterisk indicates that all mice were cured at this dose. Numbers in boldface indicate the lowest curative dose of that drug.
b The synthesis for this compound has yet to be published.
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to that of DB 820, but the further development of the prodrug
DB 289 was stopped in the meantime.
The remaining three compounds (DB 75, DB 867, and DB
1192) were capable of curing T. evansi-infected mice, at doses
of 0.5 mg/kg or lower, more effectively than the standard drugs
suramin, diminazene, and quinapyramine. Additionally, these
selected compounds are cost-efficient in terms of synthesis and
currently are not undergoing examination as lead compounds
against human trypanosomiasis. Although DB 75 did not qual-
ify for all of the specified criteria by the time these experiments
were carried out, this diamidine compound was included for
further investigations, since its prodrug, DB 289, no longer is
being developed as a human drug. In summary, three selected
diamidine compounds remain (DB 75, DB 867, and DB 1192)
that warrant continued investigation as potential clinical can-
didates against T. evansi infection in a larger animal model.
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